GW0742 for Enhanced PPARdelta Activation — Weight & Metabolism
Second-generation PPARdelta agonist. More selective than GW501516. Very limited data. No human trials. Unknown cancer risk. NOT FDA-approved.
Overview
GW0742 is a second-generation selective peroxisome proliferator-activated receptor delta (PPARδ) agonist developed as a successor compound to GW501516 (Cardarine). GW0742 demonstrates approximately 300-fold greater selectivity for PPARδ over PPARα and PPARγ compared to its predecessor, potentially offering a more targeted pharmacological profile. Like GW501516, GW0742 activates PPARδ nuclear receptors in skeletal muscle, liver, and adipose tissue, modulating the expression of genes involved in fatty acid oxidation, glucose metabolism, and lipid homeostasis. In preclinical studies, GW0742 has demonstrated effects similar to GW501516, including enhanced fatty acid oxidation, improved exercise capacity, anti-inflammatory activity, and improved lipid profiles. Several published studies have examined GW0742 in animal models of metabolic disease, heart failure, and inflammation, with generally favorable results. However, the critical question of carcinogenicity — which ended clinical development of GW501516 — has NOT been adequately addressed for GW0742. No 2-year carcinogenicity study has been published, and the structural similarity to GW501516 raises significant concerns about shared cancer-promoting properties. The mechanism of potential carcinogenicity (PPARδ-mediated promotion of cell proliferation and inhibition of apoptosis) would theoretically apply equally to any potent PPARδ agonist. No human clinical trials have been conducted with GW0742. No pharmacokinetic, safety, or efficacy data exist in humans. The compound remains a research tool with an unknown safety profile and represents an even greater leap of faith than GW501516 for any human user, as it lacks even the Phase I/II human data that was generated for Cardarine before its cancellation.
Indications
- Preclinical research tool for PPARdelta receptor biology
- Investigation of enhanced PPARdelta selectivity vs GW501516
- Preclinical studies in metabolic syndrome, heart failure, and inflammation models
- No clinical development initiated
- Research into PPARdelta-mediated fatty acid oxidation
Mechanism of Action
GW0742 taken orally with presumed adequate bioavailability based on structural class. No human pharmacokinetic parameters published. Dosing based on extrapolation from GW501516 and animal model data
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| GW0742 | 10 mg/day | Once daily | Speculative dose based on GW501516 equivalence; no human PK data |
| GW0742 | 20 mg/day | Once daily | Higher speculative dose; entirely without scientific basis for human use |
Evidence Grade
GRADE D
Safety & Contraindications
- NO human safety data whatsoever — entirely preclinical compound
- Cancer risk UNKNOWN — no carcinogenicity study published
- Structural similarity to GW501516 raises cancer concerns (PPARdelta-mediated)
- Same mechanism (PPARdelta agonism) that caused tumors with GW501516 in rats
- No pharmacokinetic data in humans — dosing is entirely speculative
- Greater selectivity for PPARdelta may increase or decrease cancer risk — unknown
- Gray-market only — no quality control or standardized products
- No drug interaction data in humans
- WADA status unclear — may be prohibited under S4.5 (metabolic modulators)
- Unknown organ toxicity profile at any dose in humans